Aeterna Zentaris Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $16.07 million
- Book Value:
- Revenue TTM:
- $4.11 million
- Operating Margin TTM:
- Gross Profit TTM:
- $5.17 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Aeterna Zentaris Inc had its IPO on 1996-07-18 under the ticker symbol AEZS.
The company operates in the Healthcare sector and Biotechnology industry. Aeterna Zentaris Inc has a staff strength of 0 employees.
Shares of Aeterna Zentaris Inc opened at $2.73 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $2.7 - $2.74, and closed at $2.72.
This is a -1.09% slip from the previous day's closing price.
A total volume of 4,600 shares were traded at the close of the day’s session.
In the last one week, shares of Aeterna Zentaris Inc have slipped by -6.85%.
Aeterna Zentaris Inc's Key Ratios
Aeterna Zentaris Inc has a market cap of $16.07 million, indicating a price to book ratio of 0.3518 and a price to sales ratio of 4.022.
In the last 12-months Aeterna Zentaris Inc’s revenue was $4.11 million with a gross profit of $5.17 million and an EBITDA of $-14357000. The EBITDA ratio measures Aeterna Zentaris Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aeterna Zentaris Inc’s operating margin was -349.82% while its return on assets stood at -12.09% with a return of equity of -24.09%.
In Q3, Aeterna Zentaris Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 76.8%.
Aeterna Zentaris Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.78 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aeterna Zentaris Inc’s profitability.
Aeterna Zentaris Inc stock is trading at a EV to sales ratio of 0.159 and a EV to EBITDA ratio of 2.5919. Its price to sales ratio in the trailing 12-months stood at 4.022.
Aeterna Zentaris Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $66.61 million
- Total Liabilities
- $5.97 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Aeterna Zentaris Inc ended 2023 with $66.61 million in total assets and $0 in total liabilities. Its intangible assets were valued at $66.61 million while shareholder equity stood at $49.42 million.
Aeterna Zentaris Inc ended 2023 with $0 in deferred long-term liabilities, $5.97 million in other current liabilities, 293410000.00 in common stock, $-338664000.00 in retained earnings and $7.03 million in goodwill. Its cash balance stood at $53.82 million and cash and short-term investments were $53.82 million. The company’s total short-term debt was $73,000 while long-term debt stood at $0.
Aeterna Zentaris Inc’s total current assets stands at $58.61 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.08 million compared to accounts payable of $720000.00 and inventory worth $238000.00.
In 2023, Aeterna Zentaris Inc's operating cash flow was $-5000.00 while its capital expenditure stood at $9000.
Comparatively, Aeterna Zentaris Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Aeterna Zentaris Inc stock is currently trading at $2.72 per share. It touched a 52-week high of $9.75 and a 52-week low of $9.75. Analysts tracking the stock have a 12-month average target price of $28.
Its 50-day moving average was $3.46 and 200-day moving average was $4.1 The short ratio stood at 6.29 indicating a short percent outstanding of 0%.
Around 33.7% of the company’s stock are held by insiders while 72% are held by institutions.
Frequently Asked Questions About Aeterna Zentaris Inc
Similar Industry Stocks (Biotechnology)
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson’s disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.